Abstract
There is growing evidence that per- and polyfluoroalkyl substances (PFAS) may alter serum lipid concentrations; however, this topic is understudied in adolescents and Latin American populations. We aimed to characterize these associations among adolescents in Ecuador’s main floricultural region.
This cross-sectional study included 97 adolescents ages 11-17 years from Pedro Moncayo County, Ecuador. Generalized estimating equation models were applied to estimate the associations of serum perfluorooctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and perfluorononanoic acid (PFNA) concentrations with serum lipids. Models were adjusted for age, gender, height, body mass index (BMI), acetylcholinesterase (AChE) activity, and hemoglobin concentrations.
We observed statistically significant sex-specific associations of all PFAS with triglycerides. Significant inverse relationships between PFAS and triglycerides were observed in females (% lipid difference per 50% increase in: PFOS= −15.0% [95%CI: −24.72, −4.06], PFNA= −25.49% [−36.93, −12.00], and PFOA= −16.55% [−28.16, −3.07]) but not in males. No associations were observed between total cholesterol, high-density lipoprotein (HDL), or low-density lipoprotein (LDL) cholesterol and any PFAS.
PFOS, PFOA, and PFNA were inversely associated with triglycerides in adolescent females but not males. Further characterization of sex-specific associations of PFAS and blood lipids in adolescents is warranted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported in this publication was supported by the National Institute of Environmental Health Sciences of the National Institutes of Health under Award Numbers (R01ES025792, R01ES030378, R21ES026084, U2CES026533). NIEHS funding was also provided to Dr. Georgia Kayser in grant numbers K01ES031697.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of University of California, San Diego and Universidad de San Francisco in Quito gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
